Cardiovascular toxicities after anthracycline and VEGF-targeted therapies in adolescent and young adult cancer survivors

Table 4 Risk for any major cardiac event^a among patients who received anthracycline

	Anthracycline
	Unadjusted			Adjusted
	N	HR	95% CI	HR	95% CI
Age at first therapy^b		1.04	(0.97 – 1.12)	1.04	(0.97 – 1.12)
Gender
Female	6	ref.		ref.
Male	12	2.15	(0.81 – 5.72)	2.41	(0.89 – 6.50)
Race
White	14	ref.		ref.
Non-white	4	1.19	(0.39 – 3.62)	1.14	(0.37 – 3.50)
Comorbidities prior to therapy^c
Hypertension	4	4.29	(1.40 – 13.10)	4.54	(1.41 – 14.63)
Diabetes	0	–		–
Dyslipidemia	0	–		–

Adjusted for age at first therapy, gender, race and comorbidities diagnosed prior to initiation of therapy
^aAny major cardiac event defined as myocardial infarction, coronary artery disease, heart failure, or cerebrovascular accident
^bHazard ratios calculated using age at first therapy as a continuous variable per one year increment
^cReference group: patients without respective comorbidity prior to treatment

ISSN: 2057-3804